Relationships Between Hepatic Steatosis and Frailty Differ by HIV Serostatus.
Journal
Journal of acquired immune deficiency syndromes (1999)
ISSN: 1944-7884
Titre abrégé: J Acquir Immune Defic Syndr
Pays: United States
ID NLM: 100892005
Informations de publication
Date de publication:
01 Oct 2024
01 Oct 2024
Historique:
received:
04
03
2024
accepted:
16
05
2024
medline:
9
9
2024
pubmed:
9
9
2024
entrez:
9
9
2024
Statut:
ppublish
Résumé
Frailty is associated with obesity-related comorbidities, but the relationship with nonalcoholic fatty liver disease (NAFLD) in people with HIV has been incompletely described. Our objective was to assess the associations between NAFLD and frailty. Cross-sectional and longitudinal analysis of men in the Multicenter AIDS Cohort Study. NAFLD was defined as a liver/spleen ratio <1.0 on abdominal computed tomography scans; frailty was defined by the frailty phenotype as having 3 of the following: weakness, slowness, weight loss, exhaustion, and low physical activity. Men without (n = 200) and with HIV (n = 292) were included. NAFLD prevalence was 21% vs 16% and frailty 12% vs 17%, respectively. Among men with NAFLD, frailty was more prevalent in men without HIV (21% vs 11%). In multivariate analysis, NAFLD was significantly associated with frailty after controlling for significant variables. Men without HIV and NAFLD had 2.6 times higher probability [95% confidence interval (CI): 1.2- to 5.7] of frailty relative to men with neither HIV nor NAFLD. This association was not seen in men with HIV. The probability of frailty was higher among men without HIV with NAFLD (27% vs 10% in men without NAFLD) but lower among men with HIV with NAFLD (14% vs 19% in men without NAFLD). No significant relationships were found in longitudinal analyses. NAFLD was independently associated with frailty among men without HIV but not men with HIV, despite increased prevalence of frailty among men with HIV. The mechanisms of the muscle-liver-adipose tissue axis underlying NAFLD might differ by HIV serostatus.
Sections du résumé
BACKGROUND
BACKGROUND
Frailty is associated with obesity-related comorbidities, but the relationship with nonalcoholic fatty liver disease (NAFLD) in people with HIV has been incompletely described. Our objective was to assess the associations between NAFLD and frailty.
METHODS
METHODS
Cross-sectional and longitudinal analysis of men in the Multicenter AIDS Cohort Study. NAFLD was defined as a liver/spleen ratio <1.0 on abdominal computed tomography scans; frailty was defined by the frailty phenotype as having 3 of the following: weakness, slowness, weight loss, exhaustion, and low physical activity.
RESULTS
RESULTS
Men without (n = 200) and with HIV (n = 292) were included. NAFLD prevalence was 21% vs 16% and frailty 12% vs 17%, respectively. Among men with NAFLD, frailty was more prevalent in men without HIV (21% vs 11%). In multivariate analysis, NAFLD was significantly associated with frailty after controlling for significant variables. Men without HIV and NAFLD had 2.6 times higher probability [95% confidence interval (CI): 1.2- to 5.7] of frailty relative to men with neither HIV nor NAFLD. This association was not seen in men with HIV. The probability of frailty was higher among men without HIV with NAFLD (27% vs 10% in men without NAFLD) but lower among men with HIV with NAFLD (14% vs 19% in men without NAFLD). No significant relationships were found in longitudinal analyses.
CONCLUSIONS
CONCLUSIONS
NAFLD was independently associated with frailty among men without HIV but not men with HIV, despite increased prevalence of frailty among men with HIV. The mechanisms of the muscle-liver-adipose tissue axis underlying NAFLD might differ by HIV serostatus.
Identifiants
pubmed: 39250650
doi: 10.1097/QAI.0000000000003477
pii: 00126334-202410010-00009
doi:
Types de publication
Journal Article
Multicenter Study
Langues
eng
Sous-ensembles de citation
IM
Pagination
165-171Subventions
Organisme : NIDDK NIH HHS
ID : R01 DK126042
Pays : United States
Organisme : NIA NIH HHS
ID : K24 AG082527
Pays : United States
Informations de copyright
Copyright © 2024 Wolters Kluwer Health, Inc. All rights reserved.
Déclaration de conflit d'intérêts
The authors have no funding or conflicts of interest to disclose.
Références
Younossi Z, Anstee QM, Marietti M, et al. Global burden of NAFLD and NASH: trends, predictions, risk factors and prevention. Nat Rev Gastroenterol Hepatol. 2018;15:11–20.
Michel M, Labenz C, Wahl A, et al. Prevalence and risk factors of nonalcoholic steatohepatitis with significant fibrosis in people with HIV. AIDS. 2022;36:1665–1674.
Lombardi R, Sambatakou H, Mariolis I, et al. Prevalence and predictors of liver steatosis and fibrosis in unselected patients with HIV mono-infection. Dig Liver Dis. 2016;48:1471–1477.
Gawrieh S, Lake JE, Debroy P, et al. Burden of fatty liver and hepatic fibrosis in persons with HIV: a diverse cross-sectional US multicenter study. Hepatology. 2023;78:578–591.
Kaplan A, Simon TG, Henson JB, et al. Brief report: relationship between nonalcoholic fatty liver disease and cardiovascular disease in persons with HIV. J Acquir Immune Defic Syndr. 2020;84:400–404.
Wegermann K, Moylan C, Naggie S. Fatty liver disease: enter the metabolic era. Curr HIV/AIDS Rep. 2023;20:405–418.
Cervo A, Milic J, Mazzola G, et al. Prevalence, predictors, and severity of lean nonalcoholic fatty liver disease in patients living with human immunodeficiency virus. Clin Infect Dis. 2020;71:e694–e701.
Vodkin I, Valasek MA, Bettencourt R, et al. Clinical, biochemical and histological differences between HIV-associated NAFLD and primary NAFLD: a case-control study. Aliment Pharmacol Ther. 2015;41:368–378.
Pembroke T, Deschenes M, Lebouché B, et al. Hepatic steatosis progresses faster in HIV mono-infected than HIV/HCV co-infected patients and is associated with liver fibrosis. J Hepatol. 2017;67:801–808.
Deeks SG. HIV infection, inflammation, immunosenescence, and aging. Annu Rev Med. 2011;62:141–155.
High KP, Brennan-Ing M, Clifford DB, et al. HIV and aging: state of knowledge and areas of critical need for research. A report to the NIH Office of AIDS Research by the HIV and Aging Working Group. J Acquir Immune Defic Syndr. 2012;60(suppl 1):S1–S18.
Clegg A, Young J, Iliffe S, et al. Frailty in elderly people. Lancet. 2013;381:752–762.
Karakousis ND, Chrysavgis L, Chatzigeorgiou A, et al. Frailty in metabolic syndrome, focusing on nonalcoholic fatty liver disease. Ann Gastroenterol. 2022;35:234–242.
Fried LP, Tangen CM, Walston J, et al. Frailty in older adults: evidence for a phenotype. J Gerontol A Biol Sci Med Sci. 2001;56:M146–M156.
Ferrucci L, Fabbri E. Inflammageing: chronic inflammation in ageing, cardiovascular disease, and frailty. Nat Rev Cardiol. 2018;15:505–522.
Altajar S, Baffy G. Skeletal muscle dysfunction in the development and progression of nonalcoholic fatty liver disease. J Clin Transl Hepatol. 2020;8:414–423.
Debroy P, Lake JE, Malagoli A, et al. Relationship between grip strength and nonalcoholic fatty liver disease in men living with HIV referred to a metabolic clinic. J Frailty Aging. 2019;8:150–153.
Zhao X, Shi X, Gu H, et al. Association between handgrip strength, nonalcoholic fatty liver disease, advanced hepatic fibrosis and its modifiers: evidence from the NHANES database of the USA. J Gastroenterol Hepatol. 2023;38:1734–1742.
Brothers TD, Kirkland S, Guaraldi G, et al. Frailty in people aging with human immunodeficiency virus (HIV) infection. J Infect Dis. 2014;210:1170–1179.
Clayton-Chubb D, Kemp WW, Majeed A, et al. Metabolic dysfunction-associated steatotic liver disease in older adults is associated with frailty and social disadvantage. Liver Int. 2024;44:39–51.
Milic J, Menozzi V, Schepis F, et al. Liver steatosis and nonalcoholic fatty liver disease with fibrosis are predictors of frailty in people living with HIV. AIDS. 2020;34:1915–1921.
Kaslow RA, Ostrow DG, Detels R, et al. The multicenter AIDS Cohort Study: rationale, organization, and selected characteristics of the participants. Am J Epidemiol. 1987;126:310–318.
Post WS, Budoff M, Kingsley L, et al. Associations between HIV infection and subclinical coronary atherosclerosis: the multicenter AIDS Cohort Study (MACS). Ann Intern Med. 2014;160:458–467.
Ketlogetswe KS, Post WS, Li X, et al. Lower adiponectin is associated with subclinical cardiovascular disease among HIV-infected men. AIDS. 2014;28:901–909.
Althoff KN, Jacobson LP, Cranston RD, et al. Age, comorbidities, and AIDS predict a frailty phenotype in men who have sex with men. J Gerontol A Biol Sci Med Sci. 2014;69:189–198.
Price JC, Seaberg EC, Latanich R, et al. Risk factors for fatty liver in the multicenter AIDS cohort study. Am J Gastroenterol. 2014;109:695–704.
Palella FJ, McKibben R, Post WS, et al. Anatomic fat depots and coronary plaque among human immunodeficiency virus-infected and uninfected men in the multicenter AIDS cohort study. Open Forum Infect Dis. 2016;3:ofw098.
Son DH, Ha HS, Park HM, et al. New markers in metabolic syndrome. In: Makowski GS, ed. Advances in Clinical Chemistry. Vol. 110. Elsevier; 2022:37–71.
Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults. Executive summary of the third report of the National cholesterol Education Program (NCEP) expert panel on detection, evaluation, and treatment of high blood cholesterol in adults (Adult Treatment Panel III). JAMA. 2001;285:2486–2497.
Craig CL, Marshall AL, Sjöström M, et al. International physical activity questionnaire: 12-country reliability and validity. Med Sci Sports Exerc. 2003;35:1381–1395.
Yilmaz Y, Ozdogan O. Liver disease as a risk factor for cognitive decline and dementia: an under-recognized issue. Hepatology. 2009;49:698.
Montano-Loza AJ, Angulo P, Meza-Junco J, et al. Sarcopenic obesity and myosteatosis are associated with higher mortality in patients with cirrhosis. J Cachexia Sarcopenia Muscle. 2016;7:126–135.
Koo BK, Kim D, Joo SK, et al. Sarcopenia is an independent risk factor for non-alcoholic steatohepatitis and significant fibrosis. J Hepatol. 2017;66:123–131.
Price JC, Wang R, Seaberg EC, et al. The association of inflammatory markers with nonalcoholic fatty liver disease differs by human immunodeficiency virus serostatus. Open Forum Infect Dis. 2017;4:ofx153.